• Capital Access

ImmuPharma Quick Reference Sheet following new Lupuzor licence


Following the recent announcement that Avion Pharmaceuticals has entered into a licence to pay up to $25m to develop (through the second phase III trial) and commercialise its major drug Lupuzor ™, ImmuPharma presents a very different opportunity compared to even a few weeks ago.


Read the full sheet here.

78 views

© 2020 by Capital Access Group.

  • Black Twitter Icon
  • Black LinkedIn Icon